BEUDAMED
    FDA Adverse Event Injury Summary report: N

    LUTONIX 035 DRUG COATED BALLOON PTA CATHETER

    MDR report key: 7261317 · Received February 9, 2018

    Report

    Report Number
    3006513822-2018-00022
    Event Type
    Injury
    Date Received
    February 9, 2018
    Date of Event
    November 20, 2017
    Report Date
    April 30, 2018
    Manufacturer
    C.R. BARD, INC. (GFO)
    Product Code
    ONU
    UDI-DI
    00801741088001
    PMA / PMN Number
    P130024
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    PO
    Reporter Occupation
    PHYSICIAN

    Narratives

    Additional Manufacturer Narrative · 0

    CORRECTED DATA: PRODUCT CLASSIFICATION CODE HAS BEEN CHANGED FROM "PRC" TO "ONU." THE PMA/510(K)# HAS BEEN CHANGED FROM "P170003" TO "P130024." THE SAMPLE WAS NOT RETURNED FROM THE USER FACILITY; THEREFORE, A DEVICE EVALUATION WAS UNABLE TO BE PERFORMED. A LOT HISTORY REVIEW REVEALED THERE IS NO SIMILAR THROMBOSIS COMPLAINTS ASSOCIATED WITH THIS LOT. A REVIEW OF THE DEVICE HISTORY RECORD (DHR) INDICATES THE LOT WAS MANUFACTURED TO SPECIFICATION. CONCLUSION: THE ACTUAL SAMPLE WAS NOT RECEIVED FOR EVALUATION. THE DHR FOUND NOTHING TO INDICATE A MANUFACTURING RELATED CAUSE FOR THIS EVENT. THE INVESTIGATOR ASSESSED THE EVENT WAS NOT RELATED TO THE STUDY DEVICE OR PROCEDURE, BUT DEFINITELY RELATED TO THE AV ACCESS CIRCUIT. BASED ON THE INSTRUCTIONS FOR USE (IFU), THE OCCURRENCE OF THROMBOSIS IS AN INHERENT RISK OF ANY PTA PROCEDURE. FURTHERMORE, PSEUDOANUERSYM IS A POTENTIAL ADVERSE EVENT, PER THE IFU. IF ADDITIONAL INFORMATION BECOMES KNOWN TO THE MANUFACTURER, A SUPPLEMENTAL REPORT WILL BE PROVIDED WITH ALL RELEVANT INFORMATION.

    Description of Event or Problem · 0

    IT WAS REPORTED THROUGH A CLINICAL REGISTRY THAT DURING THE INDEX PROCEDURE, A LUTONIX PERCUTANEOUS TRANSLUMINAL DRUG COATED BALLOON (DCB) DILATATION CATHETER WAS USED TO TREAT THE TARGET LESION LOCATED IN THE JUXTA-ANASTOMOTIC OF THE AXILLARY VEIN IN THE AV FISTULA OF THE RIGHT UPPER ARM. APPROXIMATELY 2 MONTHS AFTER THE INDEX PROCEDURE, THE PATIENT REPORTEDLY HAD A THROMBUS WITHIN THE TARGET LESION. THE HCP PERFORMED PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) WITH A SURGICAL REVISION TO EXPLORE THE VENOUS ANASTOMOSIS. A THROMBECTOMY INVOLVING THROMBOLYSIS THERAPY WAS PERFORMED, BUT THE HCP DEEMED THIS TREATMENT TO BE UNSUCCESSFUL. REPORTEDLY, RESIDUAL THROMBI WITH PSEUDOANEURYSM WERE PRESENT AFTER THE UNSUCCESSFUL PROCEDURE. THE INVESTIGATOR ASSESSED THAT THE EVENT, THROMBOSIS, WAS NOT RELATED TO THE STUDY DEVICE OR PROCEDURE, BUT DEFINITELY RELATED TO THE AV ACCESS CIRCUIT. THE SAMPLE WAS DISCARDED BY THE USER FACILITY AND IS NOT AVAILABLE FOR EVALUATION. NO SUBSEQUENT ADVERSE PATIENT EFFECTS HAVE BEEN REPORTED.

    Additional Manufacturer Narrative · 1

    ANALYSIS: THE SAMPLE WAS NOT RETURNED FROM THE USER FACILITY; THEREFORE, A DEVICE EVALUATION WAS UNABLE TO BE PERFORMED. A LOT HISTORY REVIEW REVEALED THERE IS NO SIMILAR THROMBOSIS COMPLAINTS ASSOCIATED WITH THIS LOT. A REVIEW OF THE DEVICE HISTORY RECORD (DHR) INDICATES THE LOT WAS MANUFACTURED TO SPECIFICATION. CONCLUSION: THE ACTUAL SAMPLE WAS NOT RECEIVED FOR EVALUATION. THE DHR FOUND NOTHING TO INDICATE A MANUFACTURING RELATED CAUSE FOR THIS EVENT. THE INVESTIGATOR ASSESSED THE EVENT WAS NOT RELATED TO THE STUDY DEVICE OR PROCEDURE, BUT DEFINITELY RELATED TO THE AV ACCESS CIRCUIT. BASED ON THE INSTRUCTIONS FOR USE (IFU), THE OCCURRENCE OF THROMBOSIS IS AN INHERENT RISK OF ANY PTA PROCEDURE. FURTHERMORE, PSEUDOANUERSYM IS A POTENTIAL ADVERSE EVENT, PER THE IFU. IF ADDITIONAL INFORMATION BECOMES KNOWN TO THE MANUFACTURER, A SUPPLEMENTAL REPORT WILL BE PROVIDED WITH ALL RELEVANT INFORMATION. THE INFORMATION PROVIDED BY BARD REPRESENTS ALL OF THE KNOWN INFORMATION AT THIS TIME. DESPITE GOOD FAITH EFFORTS TO OBTAIN ADDITIONAL INFORMATION, THE COMPLAINANT / REPORTER WAS UNABLE OR UNWILLING TO PROVIDE ANY FURTHER PATIENT, PRODUCT, OR PROCEDURAL DETAILS TO BARD.

    Description of Event or Problem · 1

    IT WAS REPORTED THROUGH A CLINICAL REGISTRY THAT DURING THE INDEX PROCEDURE, A LUTONIX PERCUTANEOUS TRANSLUMINAL DRUG COATED BALLOON (DCB) DILATATION CATHETER WAS USED TO TREAT THE TARGET LESION LOCATED IN THE JUXTA-ANASTOMOTIC OF THE AXILLARY VEIN IN THE AV FISTULA OF THE RIGHT UPPER ARM. APPROXIMATELY 2 MONTHS AFTER THE INDEX PROCEDURE, THE PATIENT REPORTEDLY HAD A THROMBUS WITHIN THE TARGET LESION. THE HCP PERFORMED PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY (PTA) WITH A SURGICAL REVISION TO EXPLORE THE VENOUS ANASTOMOSIS. A THROMBECTOMY INVOLVING THROMBOLYSIS THERAPY WAS PERFORMED, BUT THE HCP DEEMED THIS TREATMENT TO BE UNSUCCESSFUL. REPORTEDLY, RESIDUAL THROMBI WITH PSEUDOANEURYSM WERE PRESENT AFTER THE UNSUCCESSFUL PROCEDURE. THE INVESTIGATOR ASSESSED THAT THE EVENT, THROMBOSIS, WAS NOT RELATED TO THE STUDY DEVICE OR PROCEDURE, BUT DEFINITELY RELATED TO THE AV ACCESS CIRCUIT. THE SAMPLE WAS DISCARDED BY THE USER FACILITY AND IS NOT AVAILABLE FOR EVALUATION. NO SUBSEQUENT ADVERSE PATIENT EFFECTS HAVE BEEN REPORTED.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    104111 LUTONIX 035 DRUG COATED BALLOON PTA CATHETER DRUG COATED BALLOON PTA CATHETER ONU C.R. BARD, INC. (GFO) 9004 GFAR0920 00801741088001

    Patients

    Seq Age Sex Outcome Treatment
    1 89 YR Required Intervention